Zusammenfassung
Das biologische Altern beginnt ab 30 Jahre; als „Ältere“ werden auch in Abhängigkeit vom Betrachter Menschen der 2. Lebenshälfte, z. T. aber auch die Senioren (arbiträr Alter über 70 Jahre) bezeichnet. Im Zusammenhang mit Therapien mit Medikamenten ist die Grenze insofern fließend, als Abweichungen der Therapie von Jüngeren in unterschiedlichen Altersphasen relevant sein können. Dies soll in diesem Kapitel nach Möglichkeit berücksichtigt werden.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Anderson FH, Francis RM, Peaston RT, Waste11 HJ (1997) Androgen supplementation in eugonadal men with osteoporosis: Effects of six months’ treatment on markers of bone formation and resorption. J Bone Miner Res 12: 472-478
Barker DJP (1981) The epidemiology of Paget’s disease. Metab Bone Dis Relat Res 3:231
Bauss F (1997) Ibandronate in malignant bone diseases and osteoporosis - preclinical results. Onkologie 20: 204 - 208
Black DM, Cummings RS, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Tornern JC, Quandt SA, Reiss TF, Ensrud KE, for the Fracture Intervention Trial Research Group (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 1535-1541
Candeliere GA, Glorieux FH, Prud homme J, St.-Arnaud R (1995) Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med 332: 1546-1551
Cartwright EJ, Gordon MT, Freemont AJ, Anderson DC, Sharpe PT (1993) Paramyxoviruses and Paget’s disease. J Med Virol 40: 133-141
Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud 5, Delmas PD, Meunier PJ (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327: 1637-1642
Chapuy MC, Chapuy P, Thomas JL, Hazard MC, Meunier PJ (1996) Biochemical effects of calcium and vitamin D supplementation in elderly, institutionalized, vitamin D-deficient patients. Rev Rhm 63: 135-140
Civitelli R, Connelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C (1988) Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82: 1268-1274
Collins MR, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ (1998) Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimietic agent. J Clin Endocrinol Metab 83: 1083-1088
Consensus development conference statement (1991) J Bone Miner Res 6 [Suppl 2]:9-13
Cundy T, McAnulty K, Wattie DW, Gamble G, Rutland M, lbbertson HK (1997) Evidence for secular change in Paget’s disease. Bone 20: 69C71
Delling G (1975) Endokrine Osteopathien. Fischer, Stuttgart, S 52
Draper MW, Flowers DE, Huster WJ, Neild JA (1993) Effects of raloxifene (LY 139481 Hcl) on biochemical markers of bone and lipid metabolism in healthy postmenopausal women. In: Christiansen C, Riis B (eds) Proceedings of the 4th International Symposium on Osteoporosis and Consensus Development Conference Hong Kong. Handelstrykkeriet Aalborg ApS, pp 119-121
Francis RM, Boyle IT, Moniz C, Sutcliffe AM, Davis BS (1994) A comparison of the effects of alfacalcidol treatment and vitamin D supplementation on calcioum absorption in elderly women with osteoprosis. In: Norman AW, Bouillon R, Thomasset M (eds) Vitamin D. A pluripotent steroid hormone: Structural studies, molecular endocrinology and clinical applications. Proceedings of the Ninth Workshop on Vitamin D, Orlando, Florida, pp 850-851
Erdtsieck RJ, Pols HAP, Van Kuijk C, Birkenhäger-Frenkel DH, Zeelenberg J, Kooy PPM, Mulder P, Birkenhäger JC (1994) Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate. J Bone Miner Res 9: 277-283
Grauer A, Heichel S, Knaus J, Ziegler R (1996) Long-term effects of ibandronate treatment in Paget’s disease of bone. J Bone Miner Res [Suppl 11: 498
Hackenthal E (1988) Therapie mit Analgetika and nicht-steroidalen Antirheumatika. In: Platt D (Hrsg) Pharmakotherapie and Alter. Springer, Berlin Heidelberg New York Tokyo, S 155-190
Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnutt III CH (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med 95: 557-567
Harvey HA, Lopton A, Demers LM, Seaman J(1996) Pamidronate therapy of bone metastases in breast and prostate cancer - the U.S. experience. In: Possinger K, Ziegler R (eds) Bisphosphonate-improved treatment of osteolysis in malignant and non-malignant indications. Ciba-Geigy Verlag, Wehr, pp 21-30
Limouzin-Lamathc M-A (1988) A review of patient’s attitudes towards osteoporosis and its treatment (Italy, France and USA). In: Christiansen C (ed) New horizons in osteoporosis. Parthenon Publ. Group, Casterton Hall, Park Ridge, pp 43-49
Lippert TH, Muck OA (1997) Brustkrebsrisiko bei postmenopausaler Ostrogentherapie. Das Dilemma der Risikobeurteilung. Dtsch med Wochenschr 122: 908-911
Morrison N, Qi JC, Tokita A, Keily P, Criofts L, Ngyuen TV, Sambrook PN, Eisman JA (1994) Prediction of bone density by vitamin receptor allele. Nature 367: 284-287
Niederstadt, C, Steinhoff J (1997) Die Nieren im Alter. Z Geront Geriatrie 30:200-207
NIH consensus statement (1994) Optimal calcium intake, vol 12, p 7
Pak CYC, Zerwekh JE, Antich PP, Beil NH, Singer FR (1996) Slow-release sodium fluoride in osteoporosis. J Bone Miner Res 11: 561-564
Pak CYC, Sakhaee K, Rubin CD, Zerwekh JE (1997) Sustained-release sodium fluoride in the management of established postmenopausal osteoporosis. Am J Med Sci 313: 23-32
Paterson AHG, Powies TJ, Kanis JA, McCloskey E, Hanson J, Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59-65
Peacock M (1995) Vitamin D receptor gene alleles and osteoporosis: a contrasting view. J Bone Miner Res 10: 1294-1297
Posen S (1992) Asymptomatic primary hyperparathyroidism: the case for conservative management. Aust NZ J Med 22: 161-163
Quigley MET, Martin PL, Bumier AM, Brooks P (1987) Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 156: 1516-1523
Ravn P, Clemmesen B, Riis BJ, Christiansen C (1996) The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebocontrolled dose-finding study. Bone 19: 527-533
Ray WA, Downey W, Griffin MR, Melton III LJ (1989) Long-term use of thiazide diuretics and risk of hip fracture. Lancet 1: 687-690
Riggs BL, Hodgson SF, O’Fallon WM, Chao EYS, Wahner HW, Muhs JM, Cedel SL, Melton LJ III (1990). Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322: 802-809
Riggs BL, O’Falion WM, Lane A, Hodgson SF, Wahner HW, Muhs J, Chao E, Melton LJ III (1994) Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis. J Bone Miner Res 9: 265-275
Rowe PSN, Ong ACM, Cockerill FJ, Goulding JN, Hewison M (1996) Candidate 56 and 58 kDa protein(s) responsible for mediating the renal defects in oncogenic hypophosphatemic osteomalacia. Bone 18: 159-169
Schmorl G (1932) fiber Ostitis deformans Paget. Virchow‘s Arch 283:694
Schwabe U (1997) Rheumatische Krankheiten. In: Scholz H, Schwabe U (Hrsg) Taschen- buch der Arzneibehandlung. Fischer Verlag, Lübeck Stuttgart Jena Ulm, S 261-272
Selby SL, Peacock M (1986) Ethinyl estradiol and norethindrone in the treatment of pri- mary hyperparathyroidism in postmenopausal women. N Engl J Med 314: 1481-1485
Strasburger CJ, Schopohl J, Kann P, Oertel H für die Arbeitsgemeinschaft Hypophyse und Hypophysentumore der Deutschen Gesellschaft für Endokrinologie (1987) Diagnostische Kriterien für die Indikation zur Wachstumshormon-Substitution bei Erwachsenen. Dtsch med Wochenschr 122: 861-863
Tilyard MW, Spears GF, Thomson J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326: 357-362
Toogood AA, Adams JE, O’Neill PA, Shalet SM (1997) Elderly patients with adult-onset growth hormone deficiency are not osteopenic. J Clin Endocrin Metab 82: 1462-1466
Wasnich R, Davis J, Ross P, Vogel J (1990) Effect of thiazide on rates of bone mineral loss: a longitudinal study. BMJ 301: 1303-1305
Weinstein RS (1997) Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density. J Bone Miner Res 12: 1314-1315
Wüster C, Slenczka E, Ziegler R (1991) Erhöhte Prävalenz von Osteoporose und Arteriosklerose bei konventionell substituierter Hypophysenvorderlappeninsuffizienz: Bedarf einer zusätzlichen Wachstumshormonsubstitution? Klin Wochenschr 69: 769-773
Ziegler R, Holz G, Rotzler B, Minne H (1985) Paget‘s disease of bone in West Germany. Prevalence and distribution. Clin Orthop 194: 199-204
Ziegler R, Scheidt-Nave C, Scharla S (1995) Pathophysiology of osteoporosis: Unresolved problems and new insights. J Nutr 125: 2033-2037
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ziegler, R. (2000). Krankheiten des Bewegungsapparates. In: von Bruchhausen, F., Lemmer, B. (eds) Arzneimitteltherapie für ältere Menschen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59590-5_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-59590-5_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-64851-2
Online ISBN: 978-3-642-59590-5
eBook Packages: Springer Book Archive